Seer Inc (SEER)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralSeer bewirbt seine Proteograph-Plattform zwar durchgehend als Datenlieferant für "AI-driven biological discovery" und "AI foundation models" — doch nach dem strengen Kriterienkatalog ergibt sich in den ausgewerteten Filings (letzte 2×10-K, 4×10-Q) kein belastbarer KI-Befund: (1) Keine KI-Umsatzquelle — der Umsatz stammt ausschließlich aus dem Verkauf des Proteograph-Geräts, der Verbrauchsmaterialien, Software und Dienstleistungen (kein KI-Produkt und kein KI-Segment; die dichten Proteom-Datensätze sollen die KI der KUNDEN füttern). (2) Kein dokumentierter operativer KI-Einsatz zur Effizienz oder als internes Produkt. (3) Die zwei KI-Nennungen in den Risk Factors sind angehängte Markt-/Wettbewerbs-Floskeln ("including as a result of the impact of AI", "including through the use of AI"), kein konkretes, eigenständiges Geschäftsrisiko fürs eigene Modell — nach Vorrang-Regel damit kein Bedroht-Beleg. KI ist bei Seer Marketing-Rahmen, keine ratingrelevante Substanz.
View the full file — quotes, sources, reviewed filings
„...the proteomics market may develop more slowly or differently, including as a result of the impact of artificial intelligence (AI). In addition, the Proteograph Product Suite may not impact the field of proteomics in the same manner or degree, or within the same time frame, that NGS technologies have impacted the field of genomics, or at all."
...der Proteomik-Markt könnte sich langsamer oder anders entwickeln, auch infolge der Auswirkungen künstlicher Intelligenz (KI). Zudem könnte die Proteograph-Produktreihe das Feld der Proteomik nicht in gleicher Weise, gleichem Ausmaß oder gleichem Zeitrahmen prägen, wie es NGS-Technologien mit der Genomik getan haben, oder überhaupt nicht.
„...we cannot assure you that our competitors do not have or will not develop products or technologies, including through the use of AI, that currently or in the future will enable them to produce competitive products with greater capabilities or at lower costs than ours or that are able to run comparable experiments at a lower total experiment cost."
...wir können nicht zusichern, dass unsere Wettbewerber nicht bereits über Produkte oder Technologien verfügen oder solche — auch unter Einsatz von KI — entwickeln werden, die es ihnen gegenwärtig oder künftig ermöglichen, leistungsfähigere oder günstigere Wettbewerbsprodukte herzustellen als wir oder vergleichbare Experimente zu geringeren Gesamtkosten durchzuführen.
Filings Reviewed: 10-Q 2026-05-13 · 10-Q 2025-11-06 · 10-Q 2025-08-06 · 10-Q 2025-05-13 · 10-K 2026-03-02 · 10-K 2025-03-03
Rated on July 9, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.40 | – | 4 | -5.50 | -550.60 | -12 | -11 |
| 2025: Q1 | -0.36 | – | 4 | 37.10 | -474.40 | -11 | -12 |
| 2025: Q2 | -0.35 | – | 4 | 28.00 | -494.00 | -15 | -15 |
| 2025: Q3 | -0.33 | – | 4 | 0.70 | -459.40 | -8 | -8 |
| 2025: Q4 | -0.29 | – | 4 | 3.10 | -392.70 | -11 | -11 |
| 2026: Q1 | -0.31 | – | 3 | -35.60 | -622.20 | -15 | -16 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Seer, Inc., ein Life-Sciences-Unternehmen, entwickelt und vermarktet Produkte zur Entschlüsselung der Biologie des Proteoms zur Verbesserung der menschlichen Gesundheit in den USA, China, Australien, Europa, Israel, Japan und Südafrika.
| Employees | 124 |
|---|---|
| Headquarters | Redwood City, CA |
| Website | seer.bio |
| IPO Date | 4. Dec 2020 |
| Next Earnings | 5. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Omid C. Farokhzad M.D., Ph.D. | Founder, CEO, & Chair of the Board of Directors | 1969 |
| David R. Horn | President,Treasurer & CFO | 1968 |
| Kenny Ross | Chief Operations & Product Officer | – |
| Marissa Dixon | Chief People Officer | – |
| Serafim Batzoglou Ph.D. | Chief Data Officer | – |
| Martin Goldberg Ph.D. | Senior Vice President of Product Development | – |
| Asim Siddiqui Ph.D. | Senior Vice President of Research & Tech Development | – |
| Anthony Bazarko | Chief Commercial Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.